|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-04-08 |
A Randomised, Open-label, Single Dose, Crossover Study Investigating the Bioequivalence of Nefopam Hydrochloride 30mg Tablets With Acupan® 30mg Tablets in Healthy Subjects Under Fasting Conditions.
The purpose of this study is to compare the bioavailability of Nefopam Hydrochloride 30mg Tablets (test product) and Acupan® 30mg Tablets (reference product).
A Randomised, Open-label, Three-treatment, Single Dose, Crossover Study Investigating the Bioequivalence of Co-codamol 15/500mg Capsules With a Co-codamol 30/500mg Tablet in Healthy Subjects Under Fasting Conditions
The purpose of this study is to compare the bioavailability of co-codamol 15mg/500mg capsules (test product) and co-codamol 30mg/500mg tablets (reference product).
A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
This is a parallel group, double-blind, placebo controlled, multi-centre, randomised trial.
60 patients to be included who are adult patients admitted to hospital with a clinical diagnosis of acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Acute exacerbation of COPD will be defined as sustained worsening of the patient's condition with an increase in cough and one or more of dyspnoea, sputum volume or sputum purulence, necessitating a change in regular medication.
The primary objective of this study is to evaluate the effectiveness of standard care plus erdosteine in reducing hourly cough (24 hour cough recording using automated cough recorder) measured from baseline (Day 0) and at Day 5 of treatment, compared with standard care plus placebo.
100 项与 Galen Ltd. (Northern Ireland) 相关的临床结果
0 项与 Galen Ltd. (Northern Ireland) 相关的专利(医药)
100 项与 Galen Ltd. (Northern Ireland) 相关的药物交易
100 项与 Galen Ltd. (Northern Ireland) 相关的转化医学